Is CinCor Pharma, Inc. (CINC) a Buy, Sell, or Hold?
NASDAQ : CINC
CinCor Pharma, Inc. — Insider Trades
$29.06 USD
$0 (0.0%)
- Volume
- 0
- Average Volume
- 619.3K
- Market Capitalization
- $1.27B
- P/E Ratio
- -20.46
- Dividend Yield
- 0.00%
- Price Target
- $45.50
- Year High
- $43.15
- Year Low
- $10.53
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.53
Insider Activity Summary (Last 12 Months)
Insiders Buying
18
Insiders Selling
36
Amount of Insider Selling
$9.36M
CINC Insider Buying/Selling by Quarter
CINC Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| 5AM Partners VI, LLC | 10 percent owner | 2023-02-24 | U-Tender | 26 | 2023-02-28 |
| HEALY JAMES | director, 10 percent owner: | 2023-02-24 | U-Tender | 26 | 2023-02-27 |
| HEALY JAMES | director, 10 percent owner: | 2023-02-24 | D-Return | 0 | 2023-02-27 |
| HEALY JAMES | director, 10 percent owner: | 2022-11-28 | S-Sale | 14.32 | 2023-02-27 |
| HEALY JAMES | director, 10 percent owner: | 2023-02-24 | U-Tender | 26 | 2023-02-27 |
| Freeman Mason | officer: Chief Medical Officer | 2023-02-24 | U-Tender | 26 | 2023-02-27 |
| Freeman Mason | officer: Chief Medical Officer | 2022-06-10 | S-Sale | 15.21 | 2023-02-27 |
| Freeman Mason | officer: Chief Medical Officer | 2023-02-24 | U-Tender | 26 | 2023-02-27 |
| Freeman Mason | officer: Chief Medical Officer | 2023-02-24 | D-Return | 0 | 2023-02-27 |
| Freeman Mason | officer: Chief Medical Officer | 2023-02-24 | D-Return | 0.92 | 2023-02-27 |
| Freeman Mason | officer: Chief Medical Officer | 2023-02-24 | D-Return | 7.62 | 2023-02-27 |
| Freeman Mason | officer: Chief Medical Officer | 2023-02-24 | D-Return | 5.82 | 2023-02-27 |
| Allison David D. | director | 2023-02-24 | D-Return | 19.55 | 2023-02-24 |
| Allison David D. | director | 2023-02-24 | D-Return | 11.78 | 2023-02-24 |
| Allison David D. | director | 2023-02-24 | D-Return | 33.49 | 2023-02-24 |
| Allison David D. | director | 2023-02-24 | D-Return | 20.2 | 2023-02-24 |
| Allison David D. | director | 2023-02-24 | D-Return | 13.6 | 2023-02-24 |
| Ignelzi Troy A. | director | 2023-02-24 | D-Return | 13.6 | 2023-02-24 |
| Ignelzi Troy A. | director | 2023-02-24 | D-Return | 5.82 | 2023-02-24 |
| Kalb Michael Wayne | officer: EVP & Chief Financial Officer | 2023-02-24 | D-Return | 30.07 | 2023-02-24 |
| Kalb Michael Wayne | officer: EVP & Chief Financial Officer | 2023-02-24 | D-Return | 26 | 2023-02-24 |
| Lee June | director | 2023-02-24 | D-Return | 16 | 2023-02-24 |
| Pearce Catherine | officer: Chief Operating Officer | 2023-02-24 | U-Tender | 26 | 2023-02-24 |
| Pearce Catherine | officer: Chief Operating Officer | 2023-02-24 | U-Tender | 26 | 2023-02-24 |
| Pearce Catherine | officer: Chief Operating Officer | 2023-02-24 | D-Return | 0 | 2023-02-24 |
| Pearce Catherine | officer: Chief Operating Officer | 2023-02-24 | D-Return | 0 | 2023-02-24 |
| Pearce Catherine | officer: Chief Operating Officer | 2023-02-24 | D-Return | 2.55 | 2023-02-24 |
| THERO JOHN F | director | 2023-02-24 | D-Return | 5.82 | 2023-02-24 |
| THERO JOHN F | director | 2023-02-24 | D-Return | 13.6 | 2023-02-24 |
| de Garidel Marc | director, officer: Chief Executive Officer | 2023-02-24 | U-Tender | 26 | 2023-02-24 |
| de Garidel Marc | director, officer: Chief Executive Officer | 2023-02-24 | D-Return | 5.82 | 2023-02-24 |
| de Garidel Marc | director, officer: Chief Executive Officer | 2023-02-24 | D-Return | 0 | 2023-02-24 |
| de Garidel Marc | director, officer: Chief Executive Officer | 2023-02-24 | D-Return | 7.62 | 2023-02-24 |
| de Garidel Marc | director, officer: Chief Executive Officer | 2023-01-26 | A-Award | 0 | 2023-01-30 |
| Pearce Catherine | officer: Chief Operating Officer | 2023-01-26 | A-Award | 0 | 2023-01-30 |
| Kalb Michael Wayne | officer: EVP & Chief Financial Officer | 2023-01-26 | A-Award | 0 | 2023-01-30 |
| Freeman Mason | officer: Chief Medical Officer | 2023-01-26 | A-Award | 0 | 2023-01-30 |
| Pearce Catherine | officer: Chief Operating Officer | 2023-01-11 | M-Exempt | 0 | 2023-01-19 |
| Pearce Catherine | officer: Chief Operating Officer | 2023-01-11 | F-InKind | 28.75 | 2023-01-19 |
| Pearce Catherine | officer: Chief Operating Officer | 2023-01-11 | M-Exempt | 0 | 2023-01-19 |
| Allison David D. | director | 2023-01-06 | A-Award | 8.34 | 2023-01-10 |
| Kalb Michael Wayne | officer: EVP & Chief Financial Officer | 2022-11-04 | A-Award | 0 | 2022-11-08 |
| Kalb Michael Wayne | officer: EVP & Chief Financial Officer | 2022-11-04 | A-Award | 0 | 2022-11-08 |
| Kalb Michael Wayne | officer | 2022-11-04 | 0 | 2022-11-08 | |
| Kalb Michael Wayne | None | 2022-11-04 | None | 2022-11-08 | |
| Allison David D. | director | 2022-10-07 | A-Award | 23.85 | 2022-10-12 |
| 5AM Partners VI, LLC | 10 percent owner | 2022-08-15 | P-Purchase | 30 | 2022-08-17 |
| 5AM Partners VI, LLC | 10 percent owner | 2022-08-15 | P-Purchase | 30 | 2022-08-17 |
| 5AM Opportunities II, L.P. | director: | 2022-08-15 | P-Purchase | 30 | 2022-08-17 |
| Sofinnova Capital IX | director: | 2022-08-15 | P-Purchase | 30 | 2022-08-17 |
| Sofinnova Partners SAS | 10 percent owner | 2022-08-15 | P-Purchase | 30 | 2022-08-17 |
| Katabi Maha | director: | 2022-08-11 | P-Purchase | 30 | 2022-08-15 |
| Sofinnova Venture Partners X, L.P. | 10 percent owner | 2022-08-11 | P-Purchase | 30 | 2022-08-15 |
| HEALY JAMES | director, 10 percent owner: | 2022-08-11 | P-Purchase | 30 | 2022-08-15 |
| HEALY JAMES | director: | 2022-08-11 | P-Purchase | 30 | 2022-08-15 |
| GENERAL ATLANTIC GENPAR (BERMUDA), L.P. | 10 percent owner | 2022-08-11 | P-Purchase | 30 | 2022-08-15 |
| General Atlantic (SPV) GP, LLC | director: | 2022-08-11 | P-Purchase | 30 | 2022-08-15 |
| GENERAL ATLANTIC, L.P. | 10 percent owner | 2022-08-11 | P-Purchase | 30 | 2022-08-15 |
| General Atlantic GenPar (Lux) SCSp | director: | 2022-08-11 | P-Purchase | 30 | 2022-08-15 |
| HEALY JAMES | director, 10 percent owner: | 2022-08-05 | M-Exempt | 13.6 | 2022-08-08 |
| HEALY JAMES | director: | 2022-08-05 | M-Exempt | 0 | 2022-08-08 |
| HEALY JAMES | director, 10 percent owner: | 2022-08-05 | M-Exempt | 13.6 | 2022-08-08 |
| Allison David D. | director: | 2022-07-08 | A-Award | 14.19 | 2022-07-20 |
| Allison David D. | director | 2022-04-08 | A-Award | 19.55 | 2022-07-20 |
| Allison David D. | director: | 2022-04-08 | A-Award | 0 | 2022-05-11 |
| GENERAL ATLANTIC GENPAR (BERMUDA), L.P. | 10 percent owner | 2022-01-11 | P-Purchase | 16 | 2022-01-13 |
| GENERAL ATLANTIC GENPAR (BERMUDA), L.P. | director | 2022-01-11 | P-Purchase | 16 | 2022-01-13 |
| GENERAL ATLANTIC GENPAR (BERMUDA), L.P. | director | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| GENERAL ATLANTIC GENPAR (BERMUDA), L.P. | 10 percent owner | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| GENERAL ATLANTIC GENPAR (BERMUDA), L.P. | director | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| GENERAL ATLANTIC GENPAR (BERMUDA), L.P. | 10 percent owner | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| GENERAL ATLANTIC, L.P. | director | 2022-01-11 | P-Purchase | 16 | 2022-01-13 |
| GENERAL ATLANTIC, L.P. | 10 percent owner | 2022-01-11 | P-Purchase | 16 | 2022-01-13 |
| GENERAL ATLANTIC, L.P. | 10 percent owner | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| GENERAL ATLANTIC, L.P. | director | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| GENERAL ATLANTIC, L.P. | 10 percent owner | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| GENERAL ATLANTIC, L.P. | director | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| 5AM Partners VI, LLC | 10 percent owner | 2022-01-11 | P-Purchase | 16 | 2022-01-13 |
| 5AM Partners VI, LLC | director | 2022-01-11 | P-Purchase | 16 | 2022-01-13 |
| 5AM Partners VI, LLC | 10 percent owner | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| 5AM Partners VI, LLC | director | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| 5AM Partners VI, LLC | 10 percent owner | 2022-01-11 | P-Purchase | 16 | 2022-01-13 |
| 5AM Partners VI, LLC | director | 2022-01-11 | P-Purchase | 16 | 2022-01-13 |
| 5AM Partners VI, LLC | director | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| 5AM Partners VI, LLC | 10 percent owner | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| 5AM Partners VI, LLC | director | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| 5AM Partners VI, LLC | 10 percent owner | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| 5AM Partners VI, LLC | director | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| 5AM Partners VI, LLC | 10 percent owner | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| CinRx Pharma, LLC | 10 percent owner | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| CinRx Pharma, LLC | 10 percent owner | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| CinRx Pharma, LLC | 10 percent owner | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| Sofinnova Venture Partners X, L.P. | 10 percent owner | 2022-01-11 | P-Purchase | 16 | 2022-01-13 |
| Sofinnova Venture Partners X, L.P. | 10 percent owner | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| Sofinnova Venture Partners X, L.P. | 10 percent owner | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| Sofinnova Venture Partners X, L.P. | 10 percent owner | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| Sofinnova Partners SAS | 10 percent owner | 2022-01-11 | P-Purchase | 16 | 2022-01-13 |
| Sofinnova Partners SAS | 10 percent owner | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| Sofinnova Partners SAS | 10 percent owner | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |
| Sofinnova Partners SAS | 10 percent owner | 2022-01-11 | C-Conversion | 0 | 2022-01-13 |